From a total of 3389 screened patients diagnosed with NSCLC between 2018 and 2021, 110 were included and 3279 were excluded: 1259 were EGFR-negative, 813 had early-stage NSCLC, 689 were treated outside of IPO at any time, 493 had co-malignancies, and 25 were enrolled in clinical trials (more than one criterion may have been fulfilled). This evidence concerns the gene EGFR and non-small cell lung carcinoma.